---
title: "Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285610625.md"
description: "The clinical advancement of Soquelitinib for atopic dermatitis is progressing, with positive results from Phase 1 cohort 4. Additionally, a Phase 2 trial has been initiated during this quarter. These developments are indicative of the promising trajectory of Soquelitinib for the treatment of atopic dermatitis."
datetime: "2026-05-07T20:03:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285610625.md)
  - [en](https://longbridge.com/en/news/285610625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285610625.md)
---

# Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

The clinical advancement of Soquelitinib for atopic dermatitis is progressing, with positive results from Phase 1 cohort 4. Additionally, a Phase 2 trial has been initiated during this quarter. These developments are indicative of the promising trajectory of Soquelitinib for the treatment of atopic dermatitis.

### Related Stocks

- [CRVS.US](https://longbridge.com/en/quote/CRVS.US.md)

## Related News & Research

- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)